Use of Epidermal Growth Factor Receptor Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer to Determine Erlotinib Use as First-Line Therapy

Lung cancer is the second most common cancer and the leading cause of cancer-related deaths in the United States. Moreover, advanced non-small-cell lung cancer (NSCLC) is considered an incurable disease and current treatment approaches provide marginal improvement in overall survival at the expense...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishibe, Naoko, Carlson, Josh, Ramsey, Scott David, Freedman, Andrew, Schully, Sheri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Evidence on Genomic Tests
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3125500/
https://www.ncbi.nlm.nih.gov/pubmed/21743846
http://dx.doi.org/10.1371/currents.RRN1245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3125500/
https://www.ncbi.nlm.nih.gov/pubmed/21743846
http://dx.doi.org/10.1371/currents.RRN1245

Ejemplares similares